Classification | ESCC (n=143) | GCA (n=92) | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | Methylated | Unmethylated | P | OR | (95%CI) | N | Methylated | Unmethylated | P | OR | (95%CI) | |||||||
n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | |||||||
Gender | ||||||||||||||||||
Male | 82 | (57) | 43 | (52) | 39 | (48) | 58 | (63) | 37 | (64) | 21 | (36) | ||||||
Female | 61 | (43) | 33 | (54) | 28 | (46) | 0.84 | 0.94 | (0.48–1.82) | 34 | (37 | 23 | (68) | 11 | (32) | 0.71 | 0.84 | (0.34–2.07) |
Age (y) | ||||||||||||||||||
≤50 | 25 | (17) | 13 | (52) | 12 | (48) | 21 | (23) | 16 | (76) | 5 | (24) | ||||||
50–60 | 48 | (34) | 37 | (77) | 11 | (23) | 0.03 | 3.11 | (1.10–8.73) | 32 | (35) | 19 | (59) | 13 | (41) | 0.21 | 0.46 | (0.13–1.56) |
>60 | 70 | (49) | 26 | (37) | 44 | (63) | 0.20 | 0.55 | (0.22–1.37) | 39 | (42) | 25 | (64) | 14 | (36) | 0.34 | 0.56 | (0.17–1.85) |
Gross pathologic classification Φ | ||||||||||||||||||
1 | 38 | (27) | 18 | (47) | 20 | (53) | 17 | (18) | 10 | (59) | 7 | (41) | ||||||
2 | 25 | (17) | 16 | (64) | 9 | (36) | 0.58 | 0.74 | (0.25–2.20) | 32 | (34) | 24 | (67) | 8 | (33) | 0.25 | 2.10 | (0.60–7.36) |
3 | 29 | (20) | 19 | (66) | 10 | (34) | 0.91 | 0.92 | (0.23–3.77) | 33 | (36) | 21 | (64) | 12 | (36) | 0.74 | 1.23 | (0.37–4.06) |
4 | 19 | (13) | 15 | (79) | 4 | (31) | 0.06 | 0.39 | (0.14–1.05) | ND | ND | ND | ND | ND | ND | |||
Unclear | 32 | (22) | 8 | (25) | 24 | (75) | 10 | (11) | 5 | (50) | 5 | (50) | ||||||
Differentiation classification | ||||||||||||||||||
High | 32 | (22) | 22 | (69) | 10 | (31) | 20 | (22) | 14 | (70) | 6 | (30) | ||||||
Middle | 70 | (49) | 27 | (39) | 43 | (61) | 0.006 | 0.28 | (0.12–0.69) | 31 | (34) | 22 | (71) | 9 | (29) | 0.94 | 1.05 | (0.31–3.59) |
Low | 34 | (24) | 26 | (76) | 8 | (24) | 0.48 | 1.48 | (0.50–4.39) | 41 | (45) | 24 | (59) | 17 | (41) | 0.39 | 0.61 | (0.19–1.89) |
Unclear | 7 | (5) | 1 | (14) | 6 | (86) | ND | ND | ND | ND | ND | ND | ||||||
Tumor stage (T) classification | ||||||||||||||||||
T1+T2 | 25 | (17) | 13 | (52) | 12 | (48) | 14 | (15) | 9 | (64) | 5 | (36) | ||||||
T3+T4 | 113 | (79) | 62 | (55) | 51 | (45) | 0.38 | 1.38 | (0.68–2.82) | 78 | (85) | 51 | (65) | 27 | (35) | 0.77 | 1.20 | (0.36–4.04) |
Unclear | 5 | (3) | 2 | (40) | 3 | (60) | ND▲ | ND | ND | ND | ND | ND | ||||||
Tumor stage (N) classification | ||||||||||||||||||
N0 | 91 | (64) | 48 | (53) | 43 | (47) | 44 | (48) | 28 | (64) | 16 | (36) | ||||||
N1 | 47 | (33) | 27 | (57) | 20 | (43) | 0.60 | 1.21 | (0.60–2.46) | 48 | (52) | 32 | (67) | 16 | (33) | 0.76 | 1.143 | (0.48–2.70) |
Unclear | 5 | (3) | 1 | (20) | 4 | (80) | ND | ND | ND | ND | ND | ND | ||||||
Tumor stage (TNM) classification | ||||||||||||||||||
I+II | 91 | (64) | 47 | (52) | 44 | (48) | 47 | (51) | 30 | (64) | 17 | (36) | ||||||
III+IV | 47 | (33) | 28 | (60) | 19 | (40) | 0.38 | 1.38 | (0.68–2.82) | 45 | (49) | 30 | (67) | 15 | (33) | 0.78 | 1.13 | (0.48–2.68) |
Unclear | 5 | (3) | 1 | (20) | 4 | (80) | ND | ND | ND | ND | ND | ND | ||||||
RASSF1A protein | ||||||||||||||||||
positive | 17 | (63) | 6 | (35) | 11 | (65) | 14 | (58) | 5 | (36) | 9 | (14) | ||||||
negative | 10 | (37) | 7 | (70) | 3 | (30) | 0.09 | 0.23 | (0.04–1.25) | 10 | (42) | 10 | (100) | 0 | (0) | 0.001 |